Elevations of t-PA antigen have been linked to persons at risk in several studies involving cardiovascular events in subjects with angina pectoris and coronary artery stenosis, myocardial infarction MI , and stroke.
Furthermore, a strong support for the link between PAI-1 elevation and risk of having a MI was obtained from a study of men who had survived a first MI before the age of 45 years. Reduced t-PA activity has been reported as predictive for MI, for MI in subjects with angina pectoris, and in ischaemic disease in younger men. The results from these studies put together suggest that a state of elevated t-PA and PAI-1 antigen and reduced activity is the condition associated with cardiovascular disease.
The production of t-PA and u-PA by leukemic cells can be used to predict the prognosis and response to chemotherapy in subjects with acute myeloid leukemia. Subjects whose cells produce only t-PA have a lower chance of survival and fail to respond to chemotherapy. In contrast, subjects with u-PA producing cancer cells have a higher chance of survival and a better response to chemotherapy.
Cardiovascular diseases, such as acute myocardial infarction, stroke, and venous thromboembolism, are probably the major cause of death and disability in an adult population. The immediate underlying etiology in these conditions is often a thrombotic obstruction of critically situated blood vessels, causing a loss of blood flow to vital organs. One approach to the treatment of thrombosis consists of the intravenous infusion of plasminogen activators as clot-dissolving drugs.
The use of thrombolytic agents may occasionally require close monitoring of the components of the plasminogen activation system. Excessive thrombolytic activity is likely to cause bleeding, particulary cerebral hemorrhage, as a side-effect. An intriguing feature of the fibrinolytic system is the circadian variation in t-PA and PAI-1 that has been observed. Free t-PA levels are lowest in the morning, increase during the day and reach their peak activity level in the late afternoon.
It has been suggested that the high incidence of myocardial infarction and cerebral thrombosis in the morning hours, may be connected to the circadian rhythm of fibrinolytic activity. From mortality statistics in Greenland it is known that Eskimos have a low prevalence of myocardial infarction. This has been related to their diet, although it may also be due to the observation that Eskimos have a rapid increase in t-PA activity in the morning and a more rapid decrease in PAI-1 activity and antigen compared to Caucasians.
Because of the diurnal variation in fibrinolytic activity, sampling should always take place at the same time during the day usually between 8 a. Different stimuli, drugs, and environmental factors have been reported to modulate the fibrinolytic activity in the experimental animal as well as in humans. Examples of these are listed below in alphabetical order.
Most reports on alcohol and fibrinolysis show an increase in plasma PAI-1 levels following alcohol consumption that causes an acute decrease in t-PA activity. In a recent study of moderate alcohol consumption in a group of healthy men, it was observed that t-PA activity falls sharply after alcohol intake for the first 5 hours, although it then rises and becomes significantly higher after 13 hours.
Stanozolol produces profound change in the coagulation and fibrinolytic systems after prolonged oral administration. Peak t-PA concentrations are seen after 40 to 60 minutes of administration. A rise in the fibrinolytic activity after exercise has been reported by many authors and attributed mainly to the acute release of t-PA from the vascular endothelium.
The increase in t-PA activity is related to both the intensity and the duration of exercise and may reach 30 times the normal after a Marathon race. When comparing physically active and inactive men, it was found that t-PA activity increases more in active men and that they have a lower PAI-1 activity. A diet rich in high-complex carbohydrates and low in fat has been reported to lower both t-PA and PAI-1 antigen.
The net effect was an enhancement of fibrinolytic potential, due to the greater fall in PAI When comparing fish with lean meat, it has been observed that a fish diet leads to higher t-PA and PAI-1 antigen levels. Basal t-PA activity may increase following a 24 hour fast. This is probably a secondary reaction due to decreased PAI-1 activity.
Heparin can form complexes with t-PA. The complex has higher catalytic activity for plasminogen activation than t-PA alone, but heparin appears to inhibit the potentiating effect of fibrin on t-PA-induced plasminogen activation. Prolonged administration of unfractionated heparin and LMW heparin, induces a rise of circulating t-PA antigen levels.
The release of t-PA from the endothelium may be involved in the pathogenesis of anaphylactic shock induced by insect venom.
Levels have been found to increase about fold following a controlled insect-sting challenge in subjects with a previous history of insect-sting induced anaphylactic reaction. Mental stress releases t-PA 54 in a similar manner to that of adrenaline, 55 with increases in heart rate and systolic and diastolic blood pressures. Stress-induced release must be avoided during blood sample collection. The subject must rest both mentally and physically for minutes prior to venepuncture. Oral contraceptives may produce a significant increase in t-PA activity, not due to decreases in PAI-1 or plasminogen concentration.
Pregnancy induces marked changes in the coagulation mechanism and fibrinolytic system, changes that aim to secure hemostasis during pregnancy and delivery. The increase of t-PA antigen and the decrease of PAI-1 antigen and activity after the 38th week contributes to sustain a fibrinolytic potential capable of degrading large fibrin deposists. In addition, the release of t-PA after a venous occlusion is impaired in chronic smokers.
The venous occlusion test is often used to test subjects for their capacity to release t-PA from the occluded venous segment.
A test takes minutes and involves a blood pressure cuff on the upper arm, inflated midway between the systolic and diastolic blood pressure.
The t-PA activity rises fold and antigen levels increase times. Comparison of preocclusion with the postocclusion blood sample gives an estimate of the fibrinolytic capacity of the individual. A large variety of methods for measuring t-PA levels in human plasma have been described. These can be divided into specific t-PA assays, and non-specific global tests. Two common methods today are the global, euglobulin clot lysis time and the fibrin plate assay.
Specific t-PA assays include immunological methods which measure t-PA antigen i. The latter are either chromogenic assays using chromogenic plasmin substrates and stimulators, or bioimmunoassays that use a combination of monoclonal antibodies and chromogenic plasmin substrates.
In recent years there have been considerable improvements in the methodology of blood collection routines and sample handling. As large number of variables influence fibrinolytic activity it is important to standardize as many aspects as possible of blood collection.
Samples should be taken in the morning 8 am- 9 am from a subject who has been fasting, although a light breakfast without fat and tea or coffee can be chosen. Smoking must be avoided for at least one hour and alcohol for at least 24 hours prior to taking the sample. It is also important that the subject is resting mentally and physically prior to venepuncture.
In vivo, the concentration of active t-PA is regulated by endothelial secretion, hepatic clearance, and PAI-1, which results in a relatively stable steady-state level of active t-PA. However, when a blood sample is taken the secretion and clearance mechanisms are removed. PAI-1 will therefore continue to react with free t-PA unless preventive measures are taken. This requirement to prevent t-PA complexing in vitro is not important for immunological assays of total t-PA antigen free plus complexed , but is essential for assays measuring t-PA activity.
The latter type of test includes chromogenic substrate assays and bioimmunoassays. Bioimmunoassay for t-PA. The amount of pNA is proportional to the amount of active t-PA originally present in the sample. In the first step, t-PA complexes to an immobilized monoclonal anti-t-PA antibody without blocking the active site and unbound proteins are washed away. This results in the complete removal of interfering factors.
In the second step, human Glu-plasminogen and a chromogenic plasmin substrate are added. Plasminogen is converted to plasmin by the active t-PA, and the plasmin generated cleaves the chromogenic substrate, releasing pNA. The amount of pNA released is proportional to the amount of t-PA originally present in the sample and is measured photometrically.
The sensitivity of the bioimmunoassay makes venous occlusion tests optional and the active t-PA can be measured directly using undiluted plasma. ECLT is a global test that measures the fibrinolytic potential in plasma, and is used for estimating the t-PA activity. Select basic ads. Create a personalised ads profile. Select personalised ads. Apply market research to generate audience insights.
Measure content performance. Develop and improve products. List of Partners vendors. Tissue plasminogen activator, or tPA, is the only FDA-approved treatment for ischemic or thrombotic stroke , which is stroke caused by a blood clot interrupting blood flow to a region of the brain. It has also been used in treatment for pulmonary embolism and myocardial infarction. TPA is a blood thinner, and therefore it is not used for hemorrhagic strokes or head trauma. TPA is a naturally occurring protein found on endothelial cells, the cells that line blood vessels.
It activates the conversion of plasminogen to plasmin, an enzyme responsible for the breakdown of clots, helping restore blood flow to the brain. Prior to receiving treatment with tPA, you should expect to have a brain computerized tomography CT scan. If you have any of these conditions, not only would tPA not help you, it could cause significant harm to your health. Treatment with tPA has been effective for people with an ischemic stroke as long as it is received intravenously within up to 4.
Endovascular treatment to remove the clot or deliver tPA at the site of the clot is considered for up to 24 hours after a stroke. Guidelines for the treatment of acute stroke published by the American Heart Association in strongly recommend IV alteplase tPA within 4. This treatment approach has been shown to produce the best overall outcomes.
Protocols have been established to rapidly identify whether you could be having a stroke, so that your testing and treatment can be prompt and efficient, allowing you to receive life-saving treatments in a timely manner.
In fact, some centers are making strides in diagnosing stroke sooner than ever before via mobile stroke units. While tPA has been shown to be beneficial in the treatment of stroke, there is a risk associated with tPA treatment, even for people who have been medically cleared for tPA.
It is a powerful blood thinner, and serious side effects may occur, including the following:. If you experience any of these side effects, you should immediately inform your medical team. The best way to maximize your chances of receiving the most effective treatment for a stroke is to get to the emergency room as soon as possible.
A person who is having a stroke may not notice when they are experiencing symptoms. You can learn how to recognize a stroke so that you can get immediate help. The sooner a stroke is treated, the fewer the long-term effects.
Symptoms of a stroke include:. Stroke prevention is a vital part of a healthy lifestyle. While treatments are becoming more effective for reducing the serious consequences of a stroke, prevention is the most effective way to avoid the consequences of stroke.
Ways to control risk factors for a stroke include:. If you or a loved one has had a stroke or has received tPA for treatment of a stroke, expect a recovery that may take time. Sign up for our Health Tip of the Day newsletter, and receive daily tips that will help you live your healthiest life. Patient education: Ischemic stroke treatment Beyond the Basics. Updated Apr 08, American Stroke Association.
Why getting quick stroke treatment is important.
0コメント